Physician profile
Karen E Agersborg
NPI 1629069703
$2,520.33
in general payments reported to CMS, 2019-2025
23 companies · $606 in 2025
The $606 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $501 · 2020: $195 · 2021: $11.57 · 2022: $53.23 · 2023: $387 · 2024: $767 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.81 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,546.69 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $138.84 | 2019-2020 | |
| Amgen INC. | $118.59 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $114.95 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.29 | 2019-2020 | |
| Novo Nordisk INC | $78.83 | 2019-2020 | |
| Lilly USA, LLC | $72.86 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $44.66 | 2023-2024 | Strensiq |
| Valeritas, INC. | $36.86 | 2019 | |
| Dexcom, INC. | $35.36 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $32.51 | 2019 | |
| Medtronic Minimed, INC. | $25.17 | 2019-2020 | |
| Corcept Therapeutics | $20.49 | 2019 | |
| Shire North American Group INC | $19.20 | 2019 | |
| Glaxosmithkline, LLC. | $17.55 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.68 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.09 | 2025 | Unithroid |
| Companion Medical, INC. | $13.49 | 2019 | |
| Ascendis Pharma Endocrinology INC | $13.41 | 2023 | |
| Merck Sharp & Dohme LLC | $12.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.55 | 2019 | |
| Clarus Therapeutics INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Agersborg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.